StockData
Invivyd, Inc. logo

Invivyd, Inc. (IVVD) stock

IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3048% below fair value
$0.47−0.04 (-8.21%)

Close on Nov 18, 2026Market cap $138.68MP/E –Yield –

Invivyd operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Invivyd's operating income for the twelve months ending Jun 30, 2026 was -$112.53M. For fiscal 2025 it was -$55.56M. The highest annual figure on record is -$55.56M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$55.56M–
FY2024Dec 31, 2024-$176.88M–
FY2023Dec 31, 2023-$212.76M–
FY2022Dec 31, 2022-$248.03M–
FY2021Dec 31, 2021-$226.91M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$45.82M–
Q1 FY2026Mar 31, 2026-$43.14M–
Q4 FY2025Dec 31, 2025-$12.56M–
Q3 FY2025Sep 30, 2025-$11.02M–
Q2 FY2025Jun 30, 2025-$15.06M–
Q1 FY2025Mar 31, 2025-$16.92M–
Q4 FY2024Dec 31, 2024-$19.23M–
Q3 FY2024Sep 30, 2024-$62.31M–
Q2 FY2024Jun 30, 2024-$49.25M–
Q1 FY2024Mar 31, 2024-$46.09M–
Q4 FY2023Dec 31, 2023-$76.75M–
Q3 FY2023Sep 30, 2023-$43.06M–
Q2 FY2023Jun 30, 2023-$53.88M–
Q1 FY2023Mar 31, 2023-$39.07M–
Q4 FY2022Dec 31, 2022-$48.21M–
Q3 FY2022Sep 30, 2022-$47.33M–
Q2 FY2022Jun 30, 2022-$51.75M–
Q1 FY2022Mar 31, 2022-$100.74M–
Q4 FY2021Dec 31, 2021-$83.09M–
Q3 FY2021Sep 30, 2021-$60.42M–
Q2 FY2021Jun 30, 2021-$44.69M–
Q1 FY2021Mar 31, 2021-$38.71M–
Q3 FY2020Sep 30, 2020-$48.01M–

More Invivyd figures

See a number that looks wrong?